Avalyn Pharma

SEATTLE, WA · Founded 2011 · CIK 0001540171 · Biotech · Public

Inhaled therapeutic molecules for rare respiratory diseases

avalynpharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$242M
4 Form D · Oct 2023
36 months since last filing
Contracts
—
No federal contracts on record
Patents
30
12 granted · 18 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,090,000
Private capital raisedForm D · SEC$16,621,473
Private capital raisedForm D · SEC$35,499,998
Private capital raisedForm D · SEC$189,182,622
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2785Nuvation Bio—$275M
2786CELL REPROGRAMMING & THERAPEUTICS LLC——
2787Veradermics—$269M
2788Avalyn Pharma—$242M
2789Zylo Therapeutics Inc.—$4.9M
2790Arbor Biotechnologies—$227M
2791Metsera—$215M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 19 related persons
  • Tiba AynechiDirector
  • Lyn BaranowskiDirector · Executive Officer
  • Daniel BurgessDirector
  • Jill CarrollDirector
  • Sofia IoannidouDirector
  • Michael KamdarDirector · Executive Officer
  • Jonathan LeffDirector
  • Jonathan Leff, M.D.Director
  • Cassandra LucaDirector
  • Robert MittendorffDirector
  • Peter MoldtDirector
  • A. MontgomeryDirector · Executive Officer
  • Bruce Montgomery, M.D.Director · Executive Officer
  • Niall O'DonnellDirector
  • Ketan PatelDirector
  • Heather PrestonDirector
  • Naveed SiddiqiDirector
  • Mark Surber, Ph.D.Director · Executive Officer
  • Richard VincentExecutive Officer

Patents

USPTO · 12 granted of 30

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.